Kyowa Hakko Kogyo Co., Ltd.

Tetsuo Yoshida

Tamio Mizukami

Shiro Akinaga

Keiko Ochiai

Yasushi Sakai

Kenji Shibata

Motoo Yamasaki

Tsutomu Agatsuma

Youichi Uosaki

E2F-inhibiting compounds are represented by the formula: R &mdash;A&mdash;R wherein A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of the E2F family, which are useful as a therapeutic agent of diseases such as tumor and arteriosclerosis, for which abnormal cellular growth is implicated.

E2F activity inhibitory compounds

Disclosed is Compound GEX1 of formula (I), having excellent antitumor activity: ##STR1## wherein R.sup.1 represents hydroxy or ##STR2## R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen or hydroxy; R.sup.5 represents hydroxyl or lower alkoxy; provided that when R.sup.1 is hydroxy and R.sup.5 is methoxy, then at least one of R.sup.2, R.sup.3 and R.sup.4 is the group except for hydrogen, and pharmaceutically acceptable salts thereof.

Compound GEX1

A GE3 compound of the formula (I) having antibacterial and antitumor properties: ##STR1##

GE3 compound

Growing community of inventors

Machida, Japan

Tetsuo Yoshida